Lisdexamfetamine dimesylate: A new therapeutic option for attention-deficit hyperactivity disorder

CNS Drugs

Volumn 26, Issue 8, 2012, Pages 691-705

  Steer, Christopher ^a   Froelich, Jan ^b   Soutullo, César A ^c   Johnson, Mats ^d   Shaw, Monica ^e  

^a VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^e Shire Pharmaceuticals   (United Kingdom)

Author keywords

Attention deficit hyperactivity disorder; lisdexamfetamine; pharmacokinetics.; psychiatric disorders

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT DISEASE; ADULT DISEASE; ANOREXIA; APPETITE; AREA UNDER THE CURVE; ATTENTION; ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; INTESTINE TRANSIT TIME; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863711727     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11634340-000000000-00000     Document Type: Review

References (84)

1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46 (7): 894-921
2. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164 (6): 942-8
3. Faraone SV, Biederman J,Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36 (2): 159-65
4. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010; 19 (2): 83-105
5. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline number 72. London, UK. 2009 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12061/ 42060/42060.pdf [Accessed 2011 Mar 22]
6. Preuss U, Ralston SJ, Baldursson G, et al. Study design, baseline patient characteristics and intervention in a crosscultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006; 15 Suppl. 1: I4-14
7. Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005; 116 (3): e364-9
8. Coghill D, Soutullo C, d'Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health 2008; 2 (1): 31
9. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder: first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl. 1: I7-30
10. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15 (8): 476-95
11. Coghill D, Banaschewski T, Lecendreux M, et al. Efficacy and safety of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: a phase III, randomized, double-blind, placebo-and activecontrolled, dose-optimized study in Europe [poster no. 4.10]. Joint Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) and the Canadian Academy of Child and Adolescent Psychiatry; 2011 Oct 18-23; Toronto
12. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94 (1): 127-52
13. Diamond A. Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attentiondeficit/hyperactivity disorder (with hyperactivity). Dev Psychopathol 2005; 17 (3): 807-25
14. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998; 3 (5): 386-96
15. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 104 (6): 1300-11
16. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010; 6: 317-27
17. Madaan V. Lisdexamfetamine dimesylate for childhood ADHD. Drugs Today (Barc) 2008; 44 (5): 319-24
18. Boellner SW, Stark JG, Krishnan S, et al. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, openlabel, crossover study. Clin Ther 2010; 32 (2): 252-64
19. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007; 62 (9): 970-6
20. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008; 24 (1): 33-40
21. Krishnan SM, PennickM, Stark JG.Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig 2008; 28 (12): 745-55
22. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009; 23 (4): 410-8
23. Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010; 50: 1001-10
24. Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in schoolaged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009; 3 (1): 17
25. BramsM,MaoAR,Doyle RL.Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad Med 2008; 120 (3): 69-88
26. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008; 69 (9): 1364-73
27. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004; 18 (14): 1011-30
28. Findling RL. Evolution of the treatment of attentiondeficit/hyperactivity disorder in children: a review. Clin Ther 2008; 30 (5): 942-57
29. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010; 70 (1): 15-40
30. Giblin JM, Strobel AL. Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. J Atten Disord 2011; 15 (6): 491-8
31. Adler LA, Goodman D, Weisler R, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attentiondeficit/hyperactivity disorder. Behav Brain Funct 2009; 5: 34
32. Surman CB, Roth T. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. J Clin Psychiatry 2011; 72 (7): 903-8
33. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008; 48 (3): 293-302
34. Shire US Inc. Vyvanse prescribing information. Wayne (PA): Shire US Inc., 2012 [online]. Available from URL: http://pi.shirecontent.com/PI/PDFs/Vyvanse- USA-ENG.pdf [Accessed 2012 Apr 27]
35. Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35 (1): 180-4
36. Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009; 121 (5): 11-9
37. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45 (6): 642-57
38. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forceddose, parallel-group study. Clin Ther 2007; 29 (3): 450-63
39. Cohen J. A power primer. Psychol Bull 1992; 112 (1): 155-9
40. McGough JJ, Faraone SV. Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmont) 2009; 6 (10): 21-9
41. Findling RL. Clinical response and symptomatic remission in children treated with lisdexamfetamine dimesylate for attention-deficit/hyperactivity disorder. CNS Spectr 2010; 15 (9): 559-68
42. Swanson JM. School-based assessment and interventions for ADD students. Irvine (CA): K.C. Publishing, 1992
43. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008; 13 (7): 614-20
44. Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50 (4): 395-405
45. Brown TE, BramsM, Gao J, et al. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med 2010; 122 (5): 7-17
46. Wigal T, Brams M, Gasior M, et al. Randomized, doubleblind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010; 6 (1): 34
47. Wigal T. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med 2011; 123 (2): 169-76
48. Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr 2009; 14 (10): 573-85
49. Zoega H, Furu K, Halldorsson M, et al. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand 2011; 123: 360-7
50. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using metaanalysis. Eur Child Adolesc Psychiatry 2010; 19 (4): 353-64
51. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59 (1): 990-6
52. Jain R, Babcock T, Burtea T, et al. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health 2011; 5 (1): 35
53. Findling RL, Ginsberg LD, Jain R, et al. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol 2009; 19 (6): 649-62
54. Jain R, Babcock T, Bartea T, et al. Efficacy and safety of lisdexamphetamine dimesylate in children with attention deficit/hyperactivity disorder and recent use of methylphenidate [poster]. 57th Annual meeting of the American Academy ofChild andAdolescent Psychiatry; 2010 Oct 26-31; New York
55. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009; 23 (4): 419-27
56. Faraone SV, Spencer TJ, Kollins SH, et al. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 2010; 49 (1): 24-32
57. Faraone SV, Upadhyaya HP. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J Clin Psychiatry 2007; 68 (11): e28
58. Novak SP, Kroutil LA, Williams RL, et al. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007; 2: 32
59. Arria AM, Caldeira KM, O'Grady KE, et al. Nonmedical use of prescription stimulants among college students: associations with attention-deficit- hyperactivity disorder and polydrug use. Pharmacotherapy 2008; 28 (2): 156-69
60. Advokat CD, Guidry D, Martino L. Licit and illicit use of medications for attention-deficit hyperactivity disorder in undergraduate college students. J Am Coll Health 2008; 56 (6): 601-6
61. Varughes S, Rosen S, Ertischek M, et al. Nonmedical use surveillance and signal identification of lisdexamfetamine dimesylate, a pro-drug stimulant to treat ADHD [poster]. 2010 annual meeting of the American Academy of Addiction Psychiatry; 2010 Dec 2-5; Boca Raton (FL)
62. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2009; 70 (12): 1652-61
63. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48 (5): 484-500
64. Manos MJ. Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes. Medscape J Med 2008; 10 (1): 5
65. American Academy of Pediatrics. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128 (5): 1007-22
66. Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice (CAP) guidelines. 3rd ed. Toronto (ON): CADDRA, 2011 [online]. Available from URL: http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf [Accessed 2011May 23]
67. Soutullo Esperó n CA. Diagnó stico y tratamiento farmacolo ́ gico del trastorno por dé ficit de atenció n e hiperactividad. Med Clin (Barc) 2003; 120 (6): 222-6
68. Charach A, Cao H, Schachar R, et al. Correlates of methylphenidate use in Canadian children: a cross-sectional study. Can J Psychiatry 2006; 51 (1): 17-26
69. Miller AR, Brehaut JC, Raina P, et al. Use of medical services by methylphenidate-treated children in the general population. Ambul Pediatr 2004; 4 (2): 174-80
70. Romano E, Thornhill S, Lacourse E. An 8-year follow-up study of profiles and predictors of methylphenidate use in a nationwide sample of boys. J Pediatr 2009; 155 (5): 721-7
71. Knellwolf AL, Deligne J, Chiarotti F, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008; 64 (3): 311-7
72. Schubert I, Koster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int 2010; 107 (36): 615-21
73. Fogelman Y, Kahan E. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel: a controversial issue. Isr Med Assoc J 2001; 3 (12): 925-7
74. Fogelman Y, Vinker S, Guy N, et al. Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period. CNS Drugs 2003; 17 (12): 915-9
75. Vinker S, Vinker R, Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Investig 2006; 26 (3): 161-7
76. Donker GA, Groenhof F, van der Veen WJ. Increasing trend in prescription of methylphenidate in general practices in the north-east of The Netherlands, 1998-2003 [in Dutch]. Ned Tijdschr Geneeskd 2005; 149 (31): 1742-7
77. Ferná dez-Perez M, Iglesias-Carbajo AI. Estimacion de la prevalencia del trastorno por deficit de atencion con/sin hiperactividad en tratamiento con metilfenidato en Asturias mediante el consumo del principoi activo desede el ano 2002 al 2009 [poster]. Congress of the Spanish Association of Child and Adoloescent Psychiatry (AEPNyA); 2011 Jun 2-4; Alicante, Spain
78. Gumy C, Huissoud T, Dubois-Arber F. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics. J Atten Disord 2010; 14 (3): 267-72
79. Jick H, Kaye JA, Black C. Incidence and prevalence of drugtreated attention deficit disorder among boys in the UK. Br J Gen Pract 2004; 54 (502): 345-7
80. National Health Service. Attention deficit hyperkinetic disorders. Services over Scotland. Report of the ADHD Project User and Parent/Carer Subgroup. Edinburgh: NHS Quality Improvement Scotland, 2008 [online]. Available from URL: http://www.healthcareimprovementscotland. org/programmes/mental- health/adhd-service-improvement/adhd-services-over-scotland.aspx [Accessed 2012 Jun 5]
81. Robison LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002; 16 (2): 129-37
82. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996; 98 (6 Pt 1): 1084-8
83. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008; 42 (1): 24-31
84. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006; 163 (4): 579-85